A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. - Wikidata - awgldk - TriplyDB

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

http://www.wikidata.org/entity/Q43955899

about

Antiviral drugs for viruses other than human immunodeficiency virus How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients Advances in the management of acute retinal necrosis Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic Medical management of human immunodeficiency virus infection.Antiviral drug resistance of human cytomegalovirus.Cytomegalovirus: pathogen, paradigm, and puzzle Fundus autofluorescence changes in cytomegalovirus retinitis.Antiviral selection in the management of acute retinal necrosis.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.Optimal management of cytomegalovirus retinitis in patients with AIDS.Cytomegalovirus infection in pediatric rheumatic diseases: a review.CMV retinitis in China and SE Asia: the way forward.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity Valganciclovir: an advance in cytomegalovirus therapeutics.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Valganciclovir treatment of primary cytomegalovirus pneumonitis in an immunocompetent adult.Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.Drug delivery to the retina: challenges and opportunities.CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Human embryonic stem cells: a potential source for cellular therapy.Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Emerging trends in infections among renal transplant recipients.Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy.Emerging therapies for herpes viral infections (types 1 - 8).Therapy of other viral infections: herpes to hepatitis.Experimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA.Advances in the antiviral therapy of herpes virus infection in children.Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.Novel approaches to retinal drug delivery.Viral infection after renal transplantation: surveillance and management.Why CMV is a candidate for elimination and then eradication.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.Human cytomegalovirus infection and atherothrombosis.

P2860

Q24635330-4E4675ED-B188-44DA-8372-7AC616FD74E5 Q28069489-F8EA3874-80C2-41ED-9416-D65FD4AC5F81 Q28080841-5AD3EB01-1C27-450A-9DF7-FA65088016EA Q28259505-1DE2D270-9F99-4A5A-8823-86E083EBEAA2 Q30371489-CB894E9A-D62E-4110-97E3-3937DB0DFE12 Q30430427-2500D226-40FD-4CD0-B6B3-203A450CCD65 Q33351523-1BDA1608-3FB7-4BBD-83A1-A46EAEE4A56D Q33638295-FEADEA74-06DE-4336-B6D5-1EFF7010A876 Q33644146-D8A8D533-08A5-4AC7-9C15-553745798B52 Q33650105-94D8F651-A9C4-4770-8C00-56DD95514D08 Q33715300-4E8EB754-1777-4147-81E1-0A2E9CA4DF32 Q33819834-AE94359F-F0CE-46D7-91F1-685C7506C7B0 Q33912101-E0076A9F-C933-47B3-8DF5-63FECC4F75B8 Q34083147-88B27B3C-EC72-470F-82DD-3F6FD063D6A9 Q34212799-D24418CF-6E9E-471A-A814-36E5CC11B2E8 Q34572161-1B82F63C-86FF-4A4D-BD9A-DB2461BA9622 Q34648667-F7D8FEB5-05D6-4648-AA0E-E09BBF3E35E4 Q34670354-7438F657-B671-4E47-AD13-BEB180FE6D95 Q34713344-7F9CFBDD-E7C6-4945-9670-0D2AD407B9B9 Q34834646-87513E93-88F7-47AA-9391-D899977AE745 Q35116140-74378C23-1200-4D47-93BD-6D4241F5181D Q35185680-0A7F3C5F-F496-4644-85EF-2F81F185CD02 Q35557331-8F68F95D-712C-4192-B14E-A6B3E1B489AE Q35661046-DD69F005-179E-4DED-A505-F8303FC37553 Q35871893-716380FE-AC4D-4539-A072-7A3B7A6C55CD Q35917319-25DD34F7-DDAB-4F6C-A676-18A1F0A24328 Q35917332-7EB37CD1-5B25-4B54-8AB3-185526E3C1BC Q35917465-BCFD8CB2-85B6-4BF7-9657-4390000319E7 Q35967376-6EB6F3DD-70E2-4751-966B-3D6084131267 Q35967424-AFD95913-0BFA-427D-90B1-348A14724E5F Q36167461-158D303D-80F8-4BE4-9BC9-967FF3BACB68 Q36688958-CBB406A1-8382-4665-A2AF-8CA644877C4B Q36868806-70ED35C5-3130-4A60-A8B7-417A6C39E9F8 Q36903801-CF925484-EF5F-46A2-A78D-8C8F3CEFBB85 Q37097708-83D2713E-4869-4C45-AD83-BEB5DA8261AC Q37141395-9133F5C0-971E-4F6A-8A80-5E69C00DA273 Q37180338-FC75E71E-3B61-43C2-BFA1-0766ACD42137 Q37247594-A25DF5E2-9B9B-4385-B5C4-6366E1423908 Q37957308-4EDAE110-0CF0-4132-8C61-497BDAFD2B01 Q37967568-A235A8F9-78C4-4BD6-BD62-E70328F6CDFE

P2860

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

http://www.wikidata.org/entity/Q43955899

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@en

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@nl

type

label

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@en

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@nl

prefLabel

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@en

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

@nl

P1433

Q43955899-605FD405-8A69-40EB-B44C-4689C41B7FF7

P1476

Q43955899-41388C80-28F9-4FC4-8F00-5763DF803439

P2093

Q43955899-0930DEC3-5B61-4E70-A268-A3DBD6A9D44D

Q43955899-1E3D6DD8-3AC6-4C0F-854D-06C022AF40F3

Q43955899-33590BE5-CFC2-49C4-9D9E-87AB5D22D0ED

Q43955899-658D218B-B6C7-455D-9AED-DDCB98972DBE

Q43955899-926798D8-2A24-48AE-958A-B17A081CD703

Q43955899-D1181BFC-760E-402C-BB92-86345BE62FE1

Q43955899-DB4CBDF7-EA33-4315-8CCC-3E9A06B6E8D7

Q43955899-E69A1994-2105-47E5-A4F8-3200F95E6168

P304

Q43955899-404D123E-949C-4042-BBA4-81AF83C07269

P31

Q43955899-AC742060-8304-4C19-9617-347E444EC6AF

P356

Q43955899-391B4586-26C8-4A7B-BC08-E6E7C6727B14

P407

Q43955899-3EDEAC37-C8D1-4E22-855E-B941E1F473B5

P433

Q43955899-6DDF19EE-D033-4EA8-94B9-7D7487F79484

P478

Q43955899-52191BC0-12A7-4C33-9609-3441A75A48A6

P50

Q43955899-1F955BCA-B446-4B05-8334-0AAC85246372

P577

Q43955899-E023A65E-7B36-437E-887B-CDC5D3F47E15

P5875

Q43955899-83661E3D-2675-4C56-A9EA-6AD25F6F3F1F

P698

Q43955899-3129EFEF-667E-414B-B84D-48C8D097AEE8

P921

Q43955899-3326183B-7FA6-4C5B-A620-7322ADEE6773

P356

P1433

The New England Journal of Medicine

P1476

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis

@en

P2093

Charles A Robinson

http://www.w3.org/2001/XMLSchema#string

Daniel F Martin

http://www.w3.org/2001/XMLSchema#string

Juan Sierra-Madero

http://www.w3.org/2001/XMLSchema#string

Katherine Macey

http://www.w3.org/2001/XMLSchema#string

Mary Jean Stempien

http://www.w3.org/2001/XMLSchema#string

Panos Georgiou

http://www.w3.org/2001/XMLSchema#string

Richard A Wolitz

http://www.w3.org/2001/XMLSchema#string

Valganciclovir Study Group

http://www.w3.org/2001/XMLSchema#string

P304

1119-1126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA011759

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11418920

http://www.w3.org/2001/XMLSchema#string

P698

11948271

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus